Loading clinical trials...

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

NCT02958865•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of ulcerative colitis for greater than/equal to 3 months.
•Moderate to severe active ulcerative colitis
•Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.

Exclusion Criteria

•Pregnant or breastfeeding
•Clinical findings suggestive of Crohn's Disease
•History of bowel surgery within 6 months

Locations (189)

Dothan Surgery Center

Dothan, Alabama, United States

Gut P.C., dba Digestive Health Specialists of the Southeast

Dothan, Alabama, United States

Long Beach Clinical Trials Services Inc.

Long Beach, California, United States

Southern California Research Institute Medical Group/West Gastroenterology Medical Group/Airport En-

Los Angeles, California, United States

Clinical Application Laboratories, INC.

San Diego, California, United States

San Diego Endoscopy Center

San Diego, California, United States

Medical Associates Research Group

San Diego, California, United States

Front Range Endoscopy Center

Colorado Springs, Colorado, United States

Peak Gastroenterology Associates

Colorado Springs, Colorado, United States

Bristol Hospital

Bristol, Connecticut, United States

Key Dates

Start Date

February 3, 2017

Primary Completion Date

May 10, 2021

Completion Date

May 10, 2021

Last Updated

July 21, 2022

Enrollment

319

ACTUAL participants

Conditions

Ulcerative Colitis

Interventions

PF-06651600 or Placebo

DRUG

PF-06700841 or Placebo

DRUG

PF-06700841

DRUG

PF-06651600

DRUG

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069

Ulcerative Colitis (UC)

View study

RECRUITINGPHASE2

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

NCT06975722

Ulcerative Colitis

View study

RECRUITINGPHASE3

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Inclusion Criteria

Exclusion Criteria

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects